Vismodegib for treatment of periocular basal cell carcinoma – 6-year experience from a tertiary cancer center()()

BACKGROUND: The treatment of advanced periocular basal cell carcinomas becomes a challenge as surgery may involve highly mutilating procedures. Vismodegib is the first selective hedgehog inhibitor approved for the treatment of locally advanced tumors or metastatic disease. OBJECTIVE: Analyze the res...

Descripción completa

Detalles Bibliográficos
Autores principales: Xavier, Catarina, Lopes, Edgar, Bexiga, Catarina, Moura, Cecília, Gouveia, Emanuel, Duarte, Ana Filipa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Dermatologia 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790204/
https://www.ncbi.nlm.nih.gov/pubmed/34518037
http://dx.doi.org/10.1016/j.abd.2021.04.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790204/
https://www.ncbi.nlm.nih.gov/pubmed/34518037
http://dx.doi.org/10.1016/j.abd.2021.04.012

Ejemplares similares